Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

691628.pdf (1.02 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-09-02

Llicència de publicació

cc-by (c) Vilches, Silvia et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/176193

Effectiveness of a pharmacogenetic tool at Improving treatment efficacy in major depressive disorder: A meta-analysis of three clinical studies

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/pharmaceutics11090453

Resum

Several pharmacogenetic tests to support drug selection in psychiatric patients have recently become available. The current meta-analysis aimed to assess the clinical utility of a commercial pharmacogenetic-based tool for psychiatry (Neuropharmagen®) in the treatment management of depressive patients. Random-effects meta-analysis of clinical studies that had examined the effect of this tool on the improvement of depressive patients was performed. Effects were summarized as standardized differences between treatment groups. A total of 450 eligible subjects from three clinical studies were examined. The random effects model estimated a statistically significant effect size for the pharmacogenetic-guided prescription (d = 0.34, 95% CI = 0.11-0.56, p-value = 0.004), which corresponded to approximately a 1.8-fold increase in the odds of clinical response for pharmacogenetic-guided vs. unguided drug selection. After exclusion of patients with mild depression, the pooled estimated effect size increased to 0.42 (95% CI = 0.19-0.65, p-value = 0.004, n = 287), corresponding to an OR = 2.14 (95% CI = 1.40-3.27). These results support the clinical utility of this pharmacogenetic-based tool in the improvement of health outcomes in patients with depression, especially those with moderate-severe depression. Additional pragmatic RCTs are warranted to consolidate these findings in other patient populations.

Matèries

Antidepressius, Psiquiatria, Farmacogenètica

Matèries (anglès)

Antidepressants, Psychiatry, Pharmacogenetics

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

VILCHES, Silvia, et al. Effectiveness of a pharmacogenetic tool at Improving treatment efficacy in major depressive disorder: A meta-analysis of three clinical studies. Pharmaceutics. 2019. Vol. 11, num. 9, pags. 453. ISSN 1999-4923. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/176193

Exportar metadades

JSON - METS

Compartir registre